全文获取类型
收费全文 | 20047篇 |
免费 | 1886篇 |
国内免费 | 858篇 |
专业分类
耳鼻咽喉 | 165篇 |
儿科学 | 738篇 |
妇产科学 | 209篇 |
基础医学 | 5154篇 |
口腔科学 | 177篇 |
临床医学 | 1615篇 |
内科学 | 4313篇 |
皮肤病学 | 486篇 |
神经病学 | 981篇 |
特种医学 | 264篇 |
外国民族医学 | 8篇 |
外科学 | 687篇 |
综合类 | 2748篇 |
现状与发展 | 6篇 |
预防医学 | 1308篇 |
眼科学 | 390篇 |
药学 | 900篇 |
3篇 | |
中国医学 | 162篇 |
肿瘤学 | 2477篇 |
出版年
2024年 | 38篇 |
2023年 | 251篇 |
2022年 | 522篇 |
2021年 | 732篇 |
2020年 | 682篇 |
2019年 | 745篇 |
2018年 | 619篇 |
2017年 | 694篇 |
2016年 | 728篇 |
2015年 | 790篇 |
2014年 | 1171篇 |
2013年 | 1305篇 |
2012年 | 1044篇 |
2011年 | 1192篇 |
2010年 | 980篇 |
2009年 | 1053篇 |
2008年 | 1066篇 |
2007年 | 1061篇 |
2006年 | 1056篇 |
2005年 | 966篇 |
2004年 | 824篇 |
2003年 | 749篇 |
2002年 | 658篇 |
2001年 | 590篇 |
2000年 | 460篇 |
1999年 | 475篇 |
1998年 | 440篇 |
1997年 | 369篇 |
1996年 | 269篇 |
1995年 | 258篇 |
1994年 | 217篇 |
1993年 | 139篇 |
1992年 | 117篇 |
1991年 | 119篇 |
1990年 | 84篇 |
1989年 | 68篇 |
1988年 | 67篇 |
1987年 | 35篇 |
1986年 | 24篇 |
1985年 | 32篇 |
1984年 | 16篇 |
1983年 | 12篇 |
1982年 | 20篇 |
1981年 | 15篇 |
1980年 | 15篇 |
1979年 | 7篇 |
1978年 | 4篇 |
1977年 | 5篇 |
1976年 | 3篇 |
1970年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
Fusheng Niu Shanshan Yu Zhenxin Zhang Xin Yi Lili Ye Wei Tang Changchun Qiu Hongbo Wen Yujing Sun Jing Gao Yupu Guo 《Neurobiology of aging》2014
The mutations in the presenilin 2 (PSEN2) gene as causes of early-onset familial Alzheimer's disease (AD) have never been reported in Asia. We conducted a phenotype and pedigree study by performing neuropathological examination and target region sequencing in a family of 3 generations. Six members in this family developed dementia in their fifth decade and died in their sixth decade. The proband was diagnosed clinically with AD, which was confirmed by an autopsy. Target region sequencing showed a novel missense mutation at codon 141 (N141Y) of the PSEN2 gene that predicts an Asparagine-to-Tyrosine substitution in the affected individuals. The result was validated by Sanger sequencing in 7 family members (2 affected and 5 unaffected). The mutation was absent in the 5 clinically unaffected relatives and 188 control subjects. No influence of the APOE genotype was observed. We are the first to demonstrate a novel PSEN2 N141Y mutation in a Chinese Han family with early-onset AD. 相似文献
993.
The current literature describes pivotal mechanisms in which hepatitis B virus (HBV) induces liver diseases including inflammation, cirrhosis and hepatocellular carcinoma (HCC). It appears that differences in genetic and immunological parameters between patients and controls may be responsible for inducing the prolonged forms of the infection. Previous studies demonstrated that Toll-Like Receptors (TLRs) play key roles in viral recognition and inducing appropriate immune responses. Therefore, TLRs can be considered as key sensors for HBV recognition and subsequent induction of immune responses against this virus. It has also been shown that the TLR2 detects several microbial PAMPs either in its homodimer form or in a heterodimer with TLR1 or TLR6 and subsequently activates NF-κB in a MYD88 dependent manner. Therefore, defective TLR2 expression may result in impaired immune responses against HBV which is reported in long-term forms of hepatitis B. This review presents the recent data regarding the status and important roles played by TLR2 in HBV recognition and induction or suppression of immune responses against HBV as well as its roles in the pathogenesis of cirrhosis and HCC in prolonged hepatitis B forms. 相似文献
994.
Livia Bernardi Chiara Cupidi Francesca Frangipane Maria Anfossi Maura GalloMaria Elena Conidi Franca VassoRosanna Colao Gianfranco PuccioSabrina A.M. Curcio Maria MirabelliAlessandra Clodomiro Raffaele Di LorenzoNicoletta Smirne Raffaele MalettaAmalia C. Bruni 《Neurobiology of aging》2014
Prion protein gene mutations have been associated with clinical pictures mimicking neurodegenerative diseases different from inherited prion diseases (IPD). We report a novel missense P39L mutation in the N-terminal domain of prion protein in 2 patients affected by frontotemporal lobar degeneration syndrome, negative for mutations in genes causative of dementia. Neither the first carrier, a 67-year-old male in which the onset was a progressive non-fluent aphasia, nor the second carrier, a 78-year-old male affected by frontotemporal dementia and parkinsonism, showed any clinical or instrumental findings suggestive of IPD. Genetic screening of healthy controls and in silico analysis provide support for the potential pathogenicity of this variant. Patient phenotypes, unclassifiable as prion disease, may depend on the location of the mutation in the N-terminal domain, outside the amyloid core of pathologic prion protein, although further functional studies are required to determine whether and how this mutation exerts its pathogenic effect. However, genetic screening of prion protein gene becomes relevant in familial degenerative dementia, particularly in geographical areas with high IPD prevalence. 相似文献
995.
Narendra Joshi Sadhana Kannan Nirupama Kotian Shreyas Bhat Mithila Kale Sujata Hake 《Human immunology》2014
In our earlier studies, single nucleotide polymorphisms (SNPs) associated with anti-inflammatory cytokines were found to influence risk for breast cancer in western Indian women. Analysis of Interleukin 6 (IL-6) −174G>C polymorphism in this cohort (patients = 182; controls = 236) suggested a protective role for IL-6 −174C allele associated with the lower expression of the cytokine (OR = 0.54; 95% CI 0.32–0.89, dominant model). Together these observations suggested that in comparison to Caucasians, inflammation associated-cytokine gene polymorphisms may have higher influence on risk for cancer in this population. To examine this possibility we analyzed data assessing influence of Interleukin 6 (IL-6) −174G>C polymorphism on risk for various cancers. Overall, there was a marginally higher risk for rare allele homozygotes compared to wild type homozygotes (OR = 1.07; 95% CI 1.00–1.15). Increased risks for genitourinary cancers and for skin cancer were also indicated. The ethnicity based analysis indicated a protective effect of the minor allele in Ancestral North Indians (OR = 0.73; 95% CI 0.55–0.97). Site by ethnicity analysis once again revealed a significant protection against breast cancer (OR = 0.51; 95% CI = 0.37–0.70; dominant model) but an opposite influence on the risk of genitourinary malignancies (OR = 2.51; 95% CI 1.59–3.96; recessive model) in this population alone. The observations imply that contribution of IL-6 to inflammation or effector immunity may depend on the site of malignancy. Assessment of available data in relation to prognosis in breast cancer patients also revealed trends that are compatible with the observations of the meta-analysis. Thus, IL-6 −174G>C polymorphism clearly represents a potential modulator of risk for malignant disorders with ethnicity and site dependent trends. The results also support the possibility of higher influence of inflammation related cytokine gene polymorphisms on the risk for cancers in Ancestral North Indians. 相似文献
996.
The human leukocyte antigen (HLA)-G is a “nonclassical” major histocompatibility complex (MHC) class Ib gene, located at chromosome 6, in the 6p21.3 region. 相似文献
997.
Annette Zimpfer Stephanie Janke Maja Hühns Björn Schneider Günther Kundt Heike Zettl Ergin Kilic Matthias Maruschke Oliver W. Hakenberg Andreas Erbersdobler 《Pathology, research and practice》2014
Introduction
C-kit overexpression has previously been described in chromophobe renal cell carcinoma (cpRCC) and renal oncocytoma (RO). However, so far no KIT mutations have been found. The objective of our study was to analyse c-kit in a large cohort of renal tumors and to perform KIT mutation analysis in a subset cpRCC and RO cases with overexpression of c-kit.Materials and methods
We studied the immunohistochemical expression of c-kit on tissue microarrays containing formalin-fixed, paraffin-embedded samples of 948 patients with renal tumors. CpRCC and RO cases with c-kit overexpression (n = 23) were analyzed for KIT mutations in exons 9, 11, 13, 14, 15, and 17.Results
Expression of c-kit was found in 6/642 (0.9%) clear cell RCC, 3/154 (1.9%) papillary RCC, 54/69 (78.3%) cpRCC, 37/45 (82.2%) RO and 2/30 (6.7%) of other unclassified tumor types. In none of the RO and cpRCC cases analyzed, a KIT gene mutation was found.Conclusion
C-kit expression is found in the majority of cpRCC and RO, but these tumors do not harbor the usual c-kit activating mutations. This may have implications for the use of tyrosine kinase inhibitors in patients with advanced cpRCC and c-kit expression. 相似文献998.
《Clinical microbiology and infection》2014,20(11):1173-1180
Changes in two novel HBV serological markers, linearized hepatitis B surface antigen (HQ-HBsAg) and hepatitis B core-related antigen (HBcrAg), in the natural history of chronic hepatitis B (CHB) have not been well characterized. Serum HQ-HBsAg and HBcrAg levels of 404 Asian treatment-naïve CHB patients were analysed in a cross-sectional manner. Patients were categorized into five groups: immune tolerant (IT group, n = 52), immune clearance (IC group, n = 105), hepatitis B e antigen (HBeAg)-negative hepatitis (ENH group, n = 97), HBeAg-negative quiescent group (ENQ group, n = 95) and CHB with hepatitis B surface antigen (HBsAg) seroclearance (SC group, n = 55). HQ-HBsAg and HBcrAg were measured and correlated with HBV DNA, HBsAg, HBV genotype and clinical parameters. HQ-HBsAg showed good correlation with HBsAg, especially in the ENQ group (r = 0.874, p <0.001). Correlation of HQ-HBsAg with HBV DNA was less prominent and weakest in the ENH group (r = 0.268, p 0.008). HBcrAg correlated best with HBV DNA in the ENQ group (r = 0.537, p <0.001). In the ENQ group, 42.1% of patients had undetectable HBcrAg; this subgroup of patients, when compared with those with detectable HBcrAg, had significantly lower median HBV DNA (3.17/4.48 log IU/mL, p <0.001) and HBsAg (5.05/5.96 log mIU/mL, p <0.001) levels. Forty per cent of the SC group patients had detectable HQ-HBsAg and/or HBcrAg up to 42 months after HBsAg seroclearance. When comparing anti-HBs positivity and median time after HBsAg seroclearance in the SC group with and without detectable HQ-HBsAg/HBcrAg, there was no significant difference (22.7% and 36.4%, respectively, p 0.284, and 76.5 and 93.2 months, respectively, p 0.245). HQ-HBsAg and HBcrAg showed unique patterns of distribution throughout the five disease phases of CHB, including high detectability rates after HBsAg seroclearance, opening up different possibilities for their applicability. 相似文献
999.
1000.